Cambridge, USA-based biotech incubator Flagship Pioneering today announced it has expanded its capital base by $3.6 billion to support the creation and development of an estimated 25 breakthrough companies in human health, sustainability, and artificial intelligence.
Flagship noted that it has raised $2.6 billion into Fund VIII, in addition to side funds that include sector-specific strategic partnerships totaling $1 billion. This brings the total capital raised by Flagship into its funds since 2021 to $6.4 billion.
“At Flagship, we focus on pioneering original science, and on harnessing the ingenuity needed to invent transformative technologies and companies that improve human health as well as the sustainability of our planet,” said Noubar Afeyan, founder and chief executive of Flagship Pioneering, adding: “Our unique approach to making breakthrough scientific discoveries, combined with our track record of founding, building, and scaling companies, has led to the creation and growth of more than 100 biotechnology companies in just over two decades. And I believe Flagship’s most generative, impactful days lie ahead of us.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze